Menu Search
Equities

Zelira Therapeutics Ltd

G1G:BER

Zelira Therapeutics Ltd

Actions
  • Price (EUR)0.454
  • Today's Change0.03 / 7.08%
  • Shares traded--
  • 1 Year change-24.33%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 20:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Zelira Therapeutics Ltd's revenues fell -82.72% from 551.26k to 95.26k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 5.57m to a larger loss of 36.57m.
Gross margin91.73%
Net profit margin-3,587.90%
Operating margin-3,587.90%
Return on assets-188.05%
Return on equity-268.03%
Return on investment-246.20%
More ▼

Cash flow in AUDView more

In 2024, Zelira Therapeutics Ltd increased its cash reserves by 300.90%, or 439.95k. Cash Flow from Financing totalled 3.92m or 4,119.28% of revenues. In addition the company used 4.39m for operations while cash from investing totalled 919.74k.
Cash flow per share-3.20
Price/Cash flow per share--
Book value per share-0.3979
Tangible book value per share-0.4556
More ▼

Balance sheet in AUDView more

Zelira Therapeutics Ltd appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.6006
Quick ratio0.424
Total debt/total equity--
Total debt/total capital3.35
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.